Zura Bio Limited (ZURA)

NASDAQ: ZURA · Real-Time Price · USD

1.47

-0.07 (-4.55%)

At close: May 01, 2025, 3:59 PM

1.42

-3.07%

After-hours: May 01, 2025, 07:59 PM EDT

-4.55% (1D)

Bid	1.42
Market Cap	100.17M
Revenue (ttm)	2K
Net Income (ttm)	-47.72M
EPS (ttm)	-0.6
PE Ratio (ttm)	-2.44
Forward PE	-2.04
Analyst	Buy

Ask	1.5
Volume	275,641
Avg. Volume (20D)	318,263
Open	1.54
Previous Close	1.54
Day's Range	1.42 - 1.56
52-Week Range	0.97 - 6.35
Beta	0.08

About ZURA

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California....

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Mar 21, 2023

Employees 30

Stock Exchange NASDAQ

Ticker Symbol ZURA

Website https://zurabio.com

Full Company Profile

Analyst Forecast

According to 7 analyst ratings, the average rating for ZURA stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 923.89% from the latest price.

Stock Forecasts

Why Price Moved

1 month ago

-10.07%

Zura Bio shares are trading lower after the compan... Unlock content with Pro Subscription

News

1 month ago · businesswire.com

Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical stage, multi-asset immunology company developing novel dual-pathway anti...

2 months ago · businesswire.com

Zura Bio to Present at the Leerink Partners Global Healthcare Conference

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoim...